New drug shows promise for aggressive prostate cancer in early trial
Disease control
Not yet recruiting
This study tests a daily pill called zanzalintinib in 30 men with aggressive variant prostate cancer that has spread. The goal is to see if the drug can slow down the cancer's growth. Participants will take the drug until their cancer gets worse or side effects become too much.
Phase: PHASE2 • Sponsor: Deepak Kilari • Aim: Disease control
Last updated May 22, 2026 13:53 UTC